CliffBio
small molecule

ARMONAIR DIGIHALER

FLUTICASONE PROPIONATE

Loss of exclusivityJanuary 2041latest FDA-listed patent expiry
CompanyTeva Pharmaceutical Industries →See this company's full patent-cliff portfolio

Drug detail

Brand nameARMONAIR DIGIHALER
Active ingredientFLUTICASONE PROPIONATE
Strength0.03MG/INH
Dosage formPOWDER
RouteINHALATION
ModalitySmall molecule
FDA approvalApril 2022
Marketing statusDISCN

Listed patents

PatentExpiresType
11173259*PEDJanuary 2041—
11173259July 2040product
11344685*PEDMarch 2040—
11969544*PEDFebruary 2040—
11344685September 2039product
11969544August 2039product
10918816*PEDJune 2036—
10918816December 2035product
10195375*PEDAugust 2031—
10195375February 2031product

More from Teva Pharmaceutical Industries

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

ARMONAIR DIGIHALER patent cliff — loss of exclusivity January 2041 | CliffBio